TECHNESCAN PYP KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNESCAN PYP KIT (TECHNESCAN PYP KIT).
Technetium Tc-99m pyrophosphate binds to calcium deposits in damaged myocardial tissue, allowing scintigraphic imaging of acute myocardial infarction.
| Metabolism | Not metabolized; cleared by renal excretion. |
| Excretion | Renal: >90% as unchanged pyrophosphate; biliary/fecal: <5% |
| Half-life | Terminal half-life: 1.5–2.5 hours (biphasic: initial ~30 min, terminal ~2 h); renal impairment prolongs elimination |
| Protein binding | Plasma protein binding: <25% (primarily albumin) |
| Volume of Distribution | Vd: ~0.3 L/kg (distributes rapidly into extracellular fluid and bone) |
| Bioavailability | IV only (100% bioavailability via IV; not administered orally or IM) |
| Onset of Action | IV: Immediate accumulation in bone (within 1–2 hours for imaging) |
| Duration of Action | IV: Imaging window: 2–4 hours post-injection; significant reduction by 6 hours |
For use as a bone imaging agent: 10-20 mCi (370-740 MBq) of technetium Tc-99m pyrophosphate administered intravenously. For cardiac imaging: 15-20 mCi (555-740 MBq) intravenously. Reconstitute vial contents with sodium pertechnetate Tc-99m solution.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines are established; however, because the agent is cleared renally, consider reducing the dose in severe renal impairment (eGFR <30 mL/min/1.73 m²) and extend imaging times. Not recommended for use in anuric patients. |
| Liver impairment | No dosage adjustment required for hepatic impairment as the agent is primarily renally excreted. |
| Pediatric use | Weight-based dosing: 0.05-0.2 mCi/kg (1.85-7.4 MBq/kg) intravenously; minimum dose 0.5 mCi (18.5 MBq). For bone imaging, administer 2-3 hours before imaging; for cardiac imaging, administer 1-2 hours before imaging. |
| Geriatric use | No specific dose adjustment is required for elderly patients; however, consider renal function and general clinical status. Use the lowest effective dose to achieve diagnostic quality images. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNESCAN PYP KIT (TECHNESCAN PYP KIT).
| Breastfeeding | Technetium Tc-99m is excreted in human milk. The M/P ratio has not been established. Interrupt breastfeeding for at least 4 hours after administration and discard expressed milk during this period. Alternatively, pumping and discarding milk for 24 hours is recommended to minimize infant exposure. |
| Teratogenic Risk | Technetium Tc-99m pyrophosphate (from PYP kit) is a radiopharmaceutical. No teratogenic effects have been reported in humans; however, all radiopharmaceuticals carry a risk of fetal radiation exposure. The fetal absorbed dose is estimated at 0.0035 mGy/MBq (I trimester), 0.0019 mGy/MBq (II trimester), and 0.00063 mGy/MBq (III trimester). Avoid use in pregnancy unless benefit clearly outweighs risk. |
■ FDA Black Box Warning
Not available.
| Serious Effects |
["Hypersensitivity to pyrophosphate or any component of the kit"]
| Precautions | ["Risk of allergic reactions including anaphylaxis","Use caution in patients with renal impairment (delayed clearance)","Radiation exposure risk"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Ensure adequate maternal hydration to promote renal clearance of the radiopharmaceutical and reduce fetal radiation exposure. Consider informing the patient about radiation risks and confirm pregnancy status if applicable. |
| Fertility Effects | No known effects on fertility based on available data. Standard radiopharmaceutical precautions apply; negligible impact expected at diagnostic doses. |